Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...
Clearwater Analytics (NYSE: CWAN) ("CWAN" or the "Company"), announced that it has entered into a definitive agreement to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback